Developmental exposure to vasopressin increases aggression in adult prairie voles by Stribley, John M. & Carter, C. Sue
Developmental exposure to vasopressin increases
aggression in adult prairie voles
John M. Stribley* and C. Sue Carter†
Department of Biology, University of Maryland, College Park, MD 20742
Edited by William T. Greenough, University of Illinois at Urbana-Champaign, Urbana, IL, and approved August 19, 1999 (received for review
February 11, 1999)
Although the biological roots of aggression have been the source
of intense debate, the precise physiological mechanisms respon-
sible for aggression remain poorly understood. In most species,
aggression is more common in males than females; thus, gonadal
hormones have been a focal point for research in this field.
Although gonadal hormones have been shown to influence the
expression of aggression, in many cases aggression can continue
after castration, indicating that testicular steroids are not com-
pletely essential for the expression of aggression. Recently, the
mammalian neuropeptide arginine vasopressin (AVP) has been
implicated in aggression. AVP plays a particularly important role in
social behavior in monogamous mammals, such as prairie voles
(Microtus ochrogaster). In turn, the effects of social experiences
may be mediated by neuropeptides, including AVP. For example,
sexually naı¨ve prairie voles are rarely aggressive. However, 24 h
after the onset of mating, males of this species become signifi-
cantly aggressive toward strangers. Likewise, in adult male prairie
voles, central (intracerebroventricular) injections of AVP can sig-
nificantly increase intermale aggression, suggesting a role for AVP
in the expression of postcopulatory aggression in adult male
prairie voles. In this paper, we demonstrate that early postnatal
exposure to AVP can have long-lasting effects on the tendency to
show aggression, producing levels of aggression in sexually naı¨ve,
adult male prairie voles that are comparable to those levels
observed after mating. Females showed less aggression and were
less responsive to exogenous AVP, but the capacity of an AVP V1a
receptor antagonist to block female aggression also implicates AVP
in the development of female aggression.
Arginine vasopressin (AVP) is a nonapeptide hormone pri-marily synthesized in the paraventricular nucleus and the
supraoptic nucleus of the hypothalamus. In the brain, AVP
predominantly binds to a G protein-coupled, V1a receptor
subtype having seven transmembrane domains. V1 receptors
depend on phosphatidyl inositol hydrolysis and intracellular
calcium mobilization as part of the second messenger system for
transcriptional activation and gene expression. In addition, there
are numerous areas within the brain that receive AVP fiber
projections from the paraventricular nucleus, including the
amygdala, hippocampus, and posterior pituitary. Additional sites
of AVP synthesis include the locus ceruleus and the bed nucleus
of the stria terminalis, which sends neural projections to the
lateral septum and the lateral habenular nucleus, among others
(see refs. 1–4).
AVP and related peptides have well documented effects on a
variety of systems associated with the physiological and behav-
ioral defense of homeostasis. For example, AVP is necessary for
water retention and affects blood pressure and other aspects of
cardiovascular function (5). In rats, AVP influences the regula-
tion of the hypothalamic-pituitary-adrenal axis, and it is likely
that the central release of AVP is sensitive to stressful experi-
ences (6, 7). In addition, AVP can enhance avoidance learning
and some forms of memory (8). AVP also can influence the
expression of territorial aggression in hamsters (9) and mate
guarding in male prairie voles (Microtus ochrogaster) (10).
Although experiments conducted to determine the effects of
AVP in adult animals are common, less is known regarding the
role of this peptide during development (11, 12). Prairie voles
offer an attractive model system both for the study of aggression
and for the analysis of the developmental effects of AVP. In
adult prairie voles, AVP affects several of the behavioral char-
acteristics that define monogamy (13, 14), including high levels
of social contact (15), male parental care (16, 17), the develop-
ment of partner preferences (9, 10), and mating-induced aggres-
sive behavior (10, 18). In addition, intracerebroventricular in-
jection of AVP in adult male prairie voles has been shown to
increase exploratory activity in an elevated plus maze (19).
AVP cell bodies and receptors are present well before birth
(20), suggesting that this system is functional during the post-
natal period (21). In this paper, we hypothesized that the
behavioral systems, which are regulated by AVP in adulthood,
might also be responsive to developmental changes in AVP. This
hypothesis was tested in prairie voles by manipulating the
functional levels of AVP during the early postnatal period and
by assessing subsequent behavioral changes in adult animals.
Methods
Hormone Treatment. Prairie voles used in this study were fourth
generation descendants of a stock originally captured near
Urbana, IL. The animals were housed under a 14:10 light!dark
cycle, in polycarbonate mouse cages. Purina rabbit chow and
water were provided ad libitum. On the first postnatal day,
prairie vole pups were sexed, weighed, and toe-clipped for
identification. Males and females were randomly assigned to one
of six different groups (n ! 8–10 per group). Experimental
animals were generated from 10 independent breeding pairs
over six generations. Only one male and one female pup per litter
received hormone treatments, and like-sex siblings received
either saline (controls) or no treatment (stimulus animals) in
each generation. Over the first seven postnatal days, each animal
either received (a) 120 ng of AVP; (b) 12 ng of AVP; (c) 1.2 ng
of AVP; (d) 0.5 ng of [d(CH2)5Tyr(Me)]AVP [an AVP antag-
onist (AVPA)], each in 50 !l of saline; or (e) 50 !l of saline; or
( f ) was left untreated and unhandled. To limit the number of
groups in this experiment, only one type and dose of AVP
antagonist was chosen. The AVP antagonist used here is known
to be selective for the V1a receptor subtype found in the brain
and has been used at this dose level to successfully block the
behavioral effects of both mating and AVP in adult prairie voles
(10, 15). Although the AVP antagonist used in the aforemen-
tioned studies was administered directly into the intracerebral
ventricles of adult animals, it was assumed in our study that
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: AVP, arginine vasopressin; AVPA, an AVP antagonist [d(CH2)5Tyr(Me)]AVPI.
*Present address: Department of Obstetrics and Gynecology, 6428 Medical Science I, 1301
Catherine Street, University of Michigan, Ann Arbor, MI 48109-0617.
†To whom reprint requests should be addressed. E-mail: cc11@umail.umd.edu.
The publication costs of this article were defrayed in part by page charge payment. This
article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
§1734 solely to indicate this fact.














peripheral injections of 0.05 ng of AVP antagonist would be
suitable given the size of the neonates (1!10 of adult size) and
their altricial state. It is known that the blood–brain barrier in
altricial species is not fully formed at birth (22) and there is
mounting physiological and behavioral evidence (23–30) to
suggest that AVP can pass and perhaps play a facilitatory role in
the blood–brain barrier of neonatal and adult rats, respectively
(31–34). In our study, all of the pharmacological agents were
injected intraperitoneally once per day by using a 30-gauge,
0.5-inch hypodermic needle affixed to a 100-!l Hamilton sy-
ringe. Treated animals were returned to their litters after each
injection. All animals were weaned and paired with a same-sex
sibling on postnatal day 31.
Behavior Tests and Analysis. At 90 days of age, each subject was
tested for activity and general exploration in an elevated plus
maze (5-min test as described in refs. 18 and 19). Plus-maze
activity levels were calculated as a percentage of the entries into
the open arms divided by the sum of the open- and closed-arm
entries. Twenty-four hours later, each subject was placed for 5
min in a clean polycarbonate mouse cage (12" 18" 28 cm) with
an unfamiliar, same-sex conspecific of approximately the same
body weight. All agonistic behaviors (lunges, bites, and lateral
displays as defined in ref. 10) were recorded, and the total
frequency of these behaviors is presented here as an index of
aggression. Treatment effects were analyzed by using Kruskal–
Wallis tests, and pairwise comparisons were made by using
Mann–Whitney U tests with a level of significance of P # 0.05.
The percentage data for animals displaying at least one act of
aggression toward an unfamiliar, same-sex conspecific were
analyzed by using the Yate’s Corrected "2 test with a level of
significance assigned at P # 0.05.
Results
Males. Aggression frequencies in adult, sexually naı¨ve, male
prairie voles were significantly affected by neonatal treatment
with AVP ("2! 19.2; df! 5; P! 0.002). Males that were injected
neonatally (Fig. 1A) with 120 ng of AVP were significantly more
aggressive than were males receiving no treatment, saline, 12 ng
of AVP, or the AVP antagonist, AVPA (pairwise comparisons;
Mann–Whitney U test; P # 0.05). Further, the percentage of
animals within the 120-ng AVP dose group that displayed any
form of aggression toward an unfamiliar male conspecific was
significantly higher (Yate’s corrected "2; P # 0.05) when com-
pared with the control groups. Males that received 1.2 ng of AVP
also were more aggressive than males that were not treated or
those receiving AVPA, but the behavior of the 1.2-ng AVP group
did not differ significantly from the other AVP-treated males.
Subsequent behavioral tests of these animals supported the
assumption that the capacity of neonatal AVP to increase
aggression was not restricted to male–male aggression, because
aggression also was seen in encounters with females. Addition-
ally, in males, aggression induced by 120 ng of AVP continued
to be shown throughout the lives of the animals, and was not
further increased by sexual experience. Tendencies to display
exceptionally low levels of aggression also were consistent
throughout the lives of AVPA animals. In contrast, exploratory
behavior (Fig. 1B) was not significantly affected by treatments
with either AVP or AVPA (Kruskal–Wallis; "2! 3.8; df! 5; P!
0.58).
Females. In a concurrent study of female prairie voles, only the
lowest dose of postnatal AVP tended to increase the expression
of aggression in sexually naı¨ve, adult females (Fig. 1C; Kruskal–
Wallis; "2 ! 13.1; df ! 5; P ! 0.022). As in males, neonatal
treatments did not alter exploratory behavior (Fig. 1D). Further
pairwise comparisons revealed that females in the 1.2-ng AVP
dose group were significantly more aggressive relative to the
untreated and AVPA-treated control groups (Fig. 1C). Saline-
treated females also showed an increase in aggression in com-
parison to untreated or AVPA-treated females, but did not differ
from AVP-treated females. Although a few individual females
exhibited intense levels of aggression within several of the
AVP-treated groups, females in general were less aggressive than
their male counterparts.
Discussion
It has been proposed that hormones, which are essential for
normal physiological functions in the adult, may play an impor-
tant role during development by fine tuning their respective
receptors or neuroendocrine pathways (35–37). The results from
our study suggest that in male prairie voles the neural substrates
underlying the expression of aggression are sensitive to exposure
to AVP during the early postnatal period and that AVP may be
a component of the developmental mechanisms regulating ag-
gression later in life. Furthermore, the heightened level of
aggression observed in AVP-treated animals was secondary
neither to increased activity patterns nor to any other observed
behavioral impairments. Aggression is rare in sexually naı¨ve,
adult male prairie voles; however, after mating, prairie voles
exhibit a long-lasting, permanent increase in aggression (38, 39).
AVP is implicated in the induction of aggression both during
development and in adulthood, although whether the same
cellular mechanisms are responsible for increasing aggression in
both cases remains to be determined. For example, it is possible
that both mating (40) and developmental exposure to AVP
sensitizes AVP receptors to become more responsive to subse-
quent exposure to this peptide.
The vasopressinergic system in prairie voles appears to be
sexually dimorphic (41), with a higher concentration of immu-
noreactive AVP localized in the lateral septum and lateral
habenular nucleus of males. Our study confirms that male and
female prairie voles responded differently to AVP challenges
during early postnatal development. For example, in female
prairie voles, we observed that postnatal treatment with either
the lowest dose of AVP or the injections with the saline vehicle
was associated with increased aggression in adulthood. On the
contrary, males responded with increased aggression only at the
highest dose of AVP given. One possible explanation is that
females are more sensitive to handling stress, perhaps as medi-
ated through corticosterone during early postnatal development,
whereas males are more sensitive to AVP. Interestingly, both
males and females exhibited virtually no aggression when treated
with AVPA, suggesting that some level of endogenous AVP
production as a result of handling may be directly or indirectly
associated with the development of aggression in males and
females, respectively. Alternatively, among those groups of
females that were aggressive, only a few individual females were
exceptionally aggressive, accounting for the high level of vari-
ability we observed within the respective groups and, thus, may
require a larger sample size to be used in future studies.
It is generally assumed that perinatal androgens play a role in
mammalian sexual differentiation. However, a sex difference
with respect to the behavioral effects of AVP suggests that some
aspects of the sexual differentiation of the system responsible for
aggression may be present at birth. The developmental effects of
androgens on aggression remain to be studied in prairie voles.
However, in adult prairie voles, castration does not inhibit
aggression, and aggression appears to be independent of gonadal
steroids (N. Hastings and C.S.C., unpublished observations).
Recent experiments with prairie voles have implicated adrenal
steroids, not gonadal hormones, in the process of behavioral
masculinization in this species (42, 43). For example, postnatal
treatments with corticosterone, rather than testosterone, were
associated with increased mounting in female prairie voles, and
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neonatal castration did not reduce the tendency of males of this
species to mount in response to adult androgens.
Our study suggests the more general hypothesis that peptides
may mediate the effects of environmental cues on subsequent
adult patterns of aggression. Mechanisms such as these could
confer selective advantages by allowing individual experiences
capable of releasing AVP to produce long-lasting adjustments in
physiological and behavioral systems. For example, postnatal
f luid restriction (drought) could increase the endogenous pro-
duction of AVP and, thus, increase subsequent aggressive be-
Fig. 1. Median aggression frequency ($75% quartile range) exhibited by sexually naı¨ve, adult male (A) and female (C) prairie voles in a 5-min test with a
comparable like-sex stimulus animal. Experimental animals received either no treatment (NT); one daily intraperitoneal injection of 50 !l of physiological saline
(SAL); or 1.2 ng of AVP, 12 ng of AVP, 120 ng of AVP, or 0.5 ng of AVPA, each suspended in 50 !l of saline over the first 7 postnatal days of life. Columns sharing
letters in common are not significantly different (Mann–Whitney U; P% 0.05). The ratio of animals showing aggression within each group is noted above each
bar. Median percentage entries into the open arm of an elevated plus maze by sexually naı¨ve, adult male (B) and female (D) experimental prairie voles during
a 5-min test. There were no group differences on this measure (Mann–Whitney U; P % 0.05).














havior. Under harsh environmental conditions, a more aggres-
sive behavioral response to other animals, especially potential
competitors, might be advantageous. Alternatively, under more
benign conditions, endogenous AVP might remain low, permit-
ting lower levels of aggression, especially in reproductively naı¨ve
animals.
The clinical implications of developmental exposure to AVP
or related peptides are largely unknown. Analogues of AVP such
as desmopressin or lysine vasopressin have been used to treat
nocturnal enuresis (bed wetting) in normal children (44) or to
enhance learning and memory in mentally disabled children (45,
46), respectively. Particularly disturbing is the fact that nicotine,
a potent releaser of AVP (47–50), can freely pass both the
placental and blood–brain barriers of fetuses and their mothers
alike (51, 52). Given the recent rise in cigarette use among young
girls and pregnant teenagers in the United States (53), it is
important to understand the links among nicotine, vasopressin,
and various conduct disorders observed in children of smoking
mothers (54–59).
Given the structural similarity between oxytocin and AVP,
these peptides can affect each other’s receptors. Oxytocin (Pito-
cin) is widely used to facilitate parturition and in some cases is
used as a lactational aid. Developmental exposure to oxytocin
might act as either an agonist or an antagonist on the vaso-
pressinergic system. The long-term effects of such manipulations
have not been fully examined (30).
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